Mitarbeit an Studien - NP-MHH / consent reading

1. Standardized diagnostik workup and histopathological report on all renal transplant biopsies being taken within the IFB-Tx program following a uniquely developed protocol including a complete actual Banff classification (executive nephropathologist since 04/2014)

 

2. Clinical Protocol IM103116: Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression. Study Phase: 3b – (three renal transplant centres)

 

3. Clinical Protocol:  HGS1006-C1121 (Human Genome Sciences): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis.

Phase: 3

 

4. Clinical Protocol: QRK306: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant. Phase 3

 

5. Clinical Protocol: 200710602 „RIACT”: Double blind controlled trial on Rituximab/MabThera® in comparison to steroid alone in acute cellular rejection in renal transplants.

 

6. Clinical Protocol: Mass spectrometry (DFG): Non-invasive diagnosis of acute rejection in renal transplant patients using mass spectrometry of urine samples. A multicentre diagnostic phase 3 trial

 

7. Clinical Protocol: 3xBIOS² study: Biomarkers of renal graft injuries in kidney allograft recipients (BIOMARGIN)

 

8. Controlled trial (CL011_168): Evaluation of Avacopan in C3 glomerulopathy.

 

9. Clinical Protocol: D3461C00007: Multicentre, randomised, double-blind, placebo-controlled, Phase 2 Study Evaluation oft the efficacy and safety of Anifrolumab in adult subjects with active proliferative Lupus nephritis

 

10. Prospective multicentre study aiming at standardizing and harmonizing the nationwide anti-rejection strategy/therapy in renal transplant patients being biopsied. Study started with 2 centres: University of Schleswig-Holstein, Campus Kiel, Clinic for Nephrology and Hypertension and Department of Nephrology, Clinics Rechts der Isar, Technical University of Munich.